TrustCore Financial Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

TrustCore Financial Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-900	Closed	-$7K	–	920
2020 Q4	$7K	Buy	+900	New	+$4.64K	﹤0.01%	724
2019 Q2	–	Sell	-23,741	Closed	-$193K	–	901
2019 Q1	$193K	Hold	23,741	–	–	0.05%	160
2018 Q4	$192K	Hold	23,741	–	–	0.11%	68
2018 Q3	$181K	Sell	23,741 -2,000	-8%	-$13.4K	0.06%	163
2018 Q2	$147K	Hold	25,741	–	–	0.05%	180
2018 Q1	$123K	Hold	25,741	–	–	0.05%	185
2017 Q4	$126K	Buy	+25,741	New	+$125K	0.05%	177

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TrustCore Financial Services's BCRX Position: Q1 2021 in Review

TrustCore Financial Services sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2021, closing a stake of 900 shares — an estimated $7K sold.

TrustCore Financial Services first reported a position in BCRX in Q4 2017 and held it in 7 quarters. The position peaked at $193K in Q1 2019. 190 funds tracked by Wall St. Rank hold BCRX as of Q1 2021.

TrustCore Financial Services reported no remaining BioCryst Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
TrustCore Financial Services sold 900 BioCryst Pharmaceuticals shares in Q1 2021, an estimated $7K.
TrustCore Financial Services first reported a position in BioCryst Pharmaceuticals in Q4 2017 and held it in 7 quarters.
TrustCore Financial Services's BioCryst Pharmaceuticals position peaked at $193K in Q1 2019.
190 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2021.

Based on TrustCore Financial Services's 13F filing for Q1 2021, filed 30 Apr 2021.